Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;114(1):53-64.
doi: 10.1093/bmb/ldv019. Epub 2015 May 16.

Primary Sclerosing Cholangitis: A Clinical Update

Affiliations
Review

Primary Sclerosing Cholangitis: A Clinical Update

Kate D Williamson et al. Br Med Bull. .

Abstract

Introduction: Primary sclerosing cholangitis (PSC) is a progressive cholestatic disorder that ultimately can lead to cirrhosis, liver failure, malignancy and death. It is strongly associated with inflammatory bowel disease (IBD), and though a rare disease, its incidence is increasing. There are no proven medical therapies for PSC.

Sources of data: Ovid Medline was utilised to search for articles with keywords 'sclerosing cholangitis' and 'cholangiocarcinoma' and containing titles 'primary sclerosing cholangitis', and references of these papers were cross-referenced for further relevant manuscripts.

Areas of agreement: PSC is a rare disease, and there is a strong association with risk loci within the major histocompatibility complex and other genes common to other autoimmune diseases. PSC is a premalignant condition, associated with higher rates of hepatobiliary and colorectal cancer in patients with ulcerative colitis (UC).

Areas of controversy: The pathogenesis is unclear, and competing theories exist surrounding toxic bile acids, enhanced homing of particular T cells from the gut to the liver and increased passage of toxins to the liver through a permeable bowel wall. It is unclear whether the higher rate of colonic cancer in PSC/UC occurs in PSC/Crohn's disease. Ursodeoxycholic acid therapy reduces liver enzymes but has not been shown to improve survival. It may reduce the prevalence of bowel cancer.

Growing points: Recent genetic studies have revealed new risk loci, pointing to the importance of the immune system and its interaction with the biome.

Areas timely for developing research: On the basis of the genetic studies discussed earlier, novel agents are being developed and trialled in the treatment of PSC.

Keywords: CCR9; cholangiocarcinoma; cholestasis; colorectal cancer; genetics; inflammatory bowel disease; primary sclerosing cholangitis; sclerosing cholangitis; ursodeoxycholic acid.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

MeSH terms

Substances

Feedback